Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 12th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 12th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 29th 2015

Eli Lilly Expects Multiple Stakeholders Will Benefit from CII, a PACE Initiative

PACE has launched an evidence-based online tool, Continuous Online Indicators, which will provide information on research progress in 12 tumor types.

January 28th 2015

Segment 11: Two Paradigms Being Presented in Medical Oncology

Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.

January 28th 2015

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.

January 28th 2015

Segment 9: Who Should Order the Test?

Both Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, agree that the role of genetic counselors should be limited when order diagnostic tests in medical oncology.

January 28th 2015

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

January 28th 2015

Segment 6: Learning About CancerLinQ as It Rolls Out

Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.

January 28th 2015

Segment 5: Proper Use of Tests

Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.

January 28th 2015

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.

January 28th 2015

Amgen-Onyx File for Full Approval for Kyprolis in MM

Kyprlois is currently approval for use in multiple myeloma patients who have progressed on 2 prior therapies.

January 28th 2015

Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients

The term financial toxicity is relatively new and is being used to draw parallels between the physical toxicities of chemotherapy and the cost-related burdens cancer patients face.

January 28th 2015

Screening Does Not Save Lives Except in Very Few Exceptions

Laura Joszt, MA

Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.

January 28th 2015

Two Years In: The Impact of the ACA on Oncology

Although the Affordable Care Act (ACA) was signed into law more than 4 years ago, many aspects of it are fairly new, which makes it difficult to analyze the impact the law has had on the United States healthcare system.

January 28th 2015

Pharma Expects Push-Back on Cancer Drug Costs

After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.

January 28th 2015

Study Shows Targeted Biopsy Better Than Standard Biopsy, in Prostate Cancer

Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a large-scale study.

January 27th 2015

Segment 2: Buyer Beware in the Diagnostic Test Market

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a "buyer beware" market, according to Daniel F. Hayes, MD.

January 27th 2015

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

Although there have been some accusations of "cookbook medicine" with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.

January 27th 2015

Payer Perspectives on the Role and Impact of QOPI Certification

Although the healthcare industry values what it tends to measure, what is measured is not necessarily what should have the most value, according to John Fox, MD, senior medical director and associate vice president of medical affairs at Priority Health.

January 27th 2015

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.

January 27th 2015

Early Findings of the Oncology Patient-Centered Medical Home

One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.

January 27th 2015

CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer

The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.

January 26th 2015

Study Discovers Lack of Disease Awareness Among Women Diagnosed With Breast Cancer

The findings, published in the journal Cancer found that women diagnosed with breast cancer were not very aware of the disease characteristics such as tumor grade or stage. The researchers also found a bias based on the patient's race.

January 26th 2015

CAR T Cells and Bispecific Antibodies: A Double-Edged Sword?

Wile several big and small pharmaceutical companies have invested research efforts in developing these complex, and expensive, treatment regimens, early results from trials indicate safety issues.

January 25th 2015

ASCO Elects President for 2016-2017

Daniel F. Hayes, MD, FASCO, has been elected president of the American Society of Clinical Oncology.

January 24th 2015

Managed Care Minute: January 24, 2015

A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.

January 23rd 2015

Bayer Wants Patient Engagement in Early Drug Development

Bayer is collaborating with MD Anderson in Texas to develop a questionnaire that will query a patient's disease-related symptoms, a step to include PROs in early drug development which could help reduce adverse effects in the final product.

January 23rd 2015

Panel Discussion: Payer, Provider, and Patient Roles for Understanding the End-of-Life Care Equation: Cost vs Survival Time vs Quality of Life

Amy Berman, BS, RN, Bruce Feinberg, DO, and Patti Forest, MD, MBA, sit on the first panel discussion at Patient-Centered Oncology Care 2015 and discuss advanced directives and end-of-life care.

January 23rd 2015

Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline

January 23rd 2015

Segment 6 - Patient-Reported Outcomes and Other Important Measures

January 23rd 2015

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

January 23rd 2015

Segment 4 - Healthcare Policy: Its Impact on Innovation and Financial Waste

...

141 142 143 144 145 146 147 148 149

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions